Background: The objective of this study is to investigate the efficacy of continuous renal replacement therapy (CRRT), mainly continuous venovenous hemodiafiltration (CVVHDF), and evaluate vasoactive requirements in hyperammonemic neonates and infants. Methods: Patients who underwent CRRT for hyperammonemia were retrospectively analyzed. Measurements and Main Results: Patients in 7 of the encounters were treated solely by CVVHDF. During 3 encounters, patients who received continuous venovenous hemodialysis (CVVHD) were transitioned to CVVHDF. CVVHD was used in 3 encounters. The median 50% reduction time for ammonia was 8 h (range 3–15 h). The median duration of CRRT treatment was 40 h (range 24–89 h). Survival to hospital discharge occurred in 12 encounters (92.3%). Eleven encounters (84.6%) were treated with different vasoactive agents. In those encounters, the median vasoactive medications’ start time was the 6th hours (range 2–60 h) of CRRT. There was no association between the vasoactive index score and pre-dialysis ammonia concentration. Conclusions: CRRT achieves timely control of hypeammonemic states. Hemodynamic instability necessitating intervention with vasoactive medications is a common finding in patients with hyperammonemia.

Keywords:
Continuous hemodiafiltration, Continuous renal replacement therapy, Critical care, Critical illness, Dialysis, Removal
1.
Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.
N Engl J Med
. 2007 May;356(22):2282–92.
2.
Bachmann C. Treatment of congenital hyperammonemias.
Enzyme
. 1984;32(1):56–64.
3.
Auron A, Brophy PD. Hyperammonemia in review: pathophysiology, diagnosis, and treatment.
Pediatr Nephrol
. 2012 Feb;27(2):207–22.
4.
Picca S, Dionisi-Vici C, Abeni D, Pastore A, Rizzo C, Orzalesi M, et al. Extracorporeal dialysis in neonatal hyperammonemia: modalities and prognostic indicators.
Pediatr Nephrol
. 2001 Nov;16(11):862–7.
5.
Picca S, Dionisi-Vici C, Bartuli A, De Palo T, Papadia F, Montini G, et al. Short-term survival of hyperammonemic neonates treated with dialysis.
Pediatr Nephrol
. 2015 May;30(5):839–47.
6.
Rajpoot DK, Gargus JJ. Acute hemodialysis for hyperammonemia in small neonates.
Pediatr Nephrol
. 2004 Apr;19(4):390–5.
7.
Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and SNAPPE-II: simplified newborn illness severity and mortality risk scores.
J Pediatr
. 2001 Jan;138(1):92–100.
8.
Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated pediatric risk of mortality score.
Crit Care Med
. 1996 May;24(5):743–52.
9.
Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study.
Lancet
. 2003 Jul;362(9379):192–7.
10.
Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale.
Lancet
. 1974 Jul;2(7872):81–4.
11.
Frankenburg WK, Dodds J, Archer P, Shapiro H, Bresnick B. The Denver II: a major revision and restandardization of the Denver Developmental Screening Test.
Pediatrics
. 1992 Jan;89(1):91–7.
12.
Strazdins V, Watson AR, Harvey B; European Pediatric Peritoneal Sialysis Working Group. Renal replacement therapy for acute renal failure in children: european guidelines.
Pediatr Nephrol
. 2004 Feb;19(2):199–207.
13.
Pasko DA, Mottes TA, Mueller BA. Pre dialysis of blood prime in continuous hemodialysis normalizes pH and electrolytes.
Pediatr Nephrol
. 2003 Nov;18(11):1177–83.
14.
Wernovsky G, Wypij D, Jonas RA, Mayer JE Jr, Hanley FL, Hickey PR, et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest.
Circulation
. 1995 Oct;92(8):2226–35.
15.
Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass.
Pediatr Crit Care Med
. 2010 Mar;11(2):234–8.
16.
Ring E, Zobel G, Stöckler S. Clearance of toxic metabolites during therapy for inborn errors of metabolism.
J Pediatr
. 1990 Aug;117(2 Pt 1):349–50.
17.
Thompson GN, Butt WW, Shann FA, Kirby DM, Henning RD, Howells DW, et al. Continuous venovenous hemofiltration in the management of acute decompensation in inborn errors of metabolism.
J Pediatr
. 1991 Jun;118(6):879–84.
18.
Sadowski RH, Harmon WE, Jabs K. Acute hemodialysis of infants weighing less than five kilograms.
Kidney Int
. 1994 Mar;45(3):903–6.
19.
Tsai IJ, Hwu WL, Huang SC, Lee NC, Wu ET, Chien YH, et al. Efficacy and safety of intermittent hemodialysis in infants and young children with inborn errors of metabolism.
Pediatr Nephrol
. 2014 Jan;29(1):111–6.
20.
Wong KY, Wong SN, Lam SY, Tam S, Tsoi NS. Ammonia clearance by peritoneal dialysis and continuous arteriovenous hemodiafiltration.
Pediatr Nephrol
. 1998 Sep;12(7):589–91.
21.
Braun MC, Welch TR. Continuous venovenous hemodiafiltration in the treatment of acute hyperammonemia.
Am J Nephrol
. 1998;18(6):531–3.
22.
Schaefer F, Straube E, Oh J, Mehls O, Mayatepek E. Dialysis in neonates with inborn errors of metabolism.
Nephrol Dial Transplant
. 1999 Apr;14(4):910–8.
23.
Arbeiter AK, Kranz B, Wingen AM, Bonzel KE, Dohna-Schwake C, Hanssler L, et al. Continuous venovenous haemodialysis (CVVHD) and continuous peritoneal dialysis (CPD) in the acute management of 21 children with inborn errors of metabolism.
Nephrol Dial Transplant
. 2010 Apr;25(4):1257–65.
24.
McBryde KD, Kershaw DB, Bunchman TE, Maxvold NJ, Mottes TA, Kudelka TL, et al. Renal replacement therapy in the treatment of confirmed or suspected inborn errors of metabolism.
J Pediatr
. 2006 Jun;148(6):770–8.
25.
Bunchman TE, Barletta GM, Winters JW, Gardner JJ, Crumb TL, McBryde KD. Phenylacetate and benzoate clearance in a hyperammonemic infant on sequential hemodialysis and hemofiltration.
Pediatr Nephrol
. 2007 Jul;22(7):1062–5.
26.
Semama DS, Huet F, Gouyon JB, Lallemant C, Desgres J. Use of peritoneal dialysis, continuous arteriovenous hemofiltration, and continuous arteriovenous hemodiafiltration for removal of ammonium chloride and glutamine in rabbits.
J Pediatr
. 1995 May;126(5 Pt 1):742–6.
27.
Westrope C, Morris K, Burford D, Morrison G. Continuous hemofiltration in the control of neonatal hyperammonemia: a 10-year experience.
Pediatr Nephrol
. 2010 Sep;25(9):1725–30.
28.
Spinale JM, Laskin BL, Sondheimer N, Swartz SJ, Goldstein SL. High-dose continuous renal replacement therapy for neonatal hyperammonemia.
Pediatr Nephrol
. 2013 Jun;28(6):983–6.
29.
Lai YC, Huang HP, Tsai IJ, Tsau YK. High-volume continuous venovenous hemofiltration as an effective therapy for acute management of inborn errors of metabolism in young children.
Blood Purif
. 2007;25(4):303–8.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.